Calverley
PM, Boonsawat Z, Zhong N, Peterson S and Olsson H. Maintenance
therapy with budesonide and formoterol in chronic obstructive
pulmonary disease. Eur Resp J 2003; 22;
912-919.
Global
Initiative for Chronic Obstructive Lung Disease (GOLD). Global
Strategy For the Diagnosis, Management, and Prevention of COPD
NHLBI/WHO Workshop Report. http://www.goldcopd.com
Jones
PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure
of health status for chronic airflow limitation. Am Rev Respir Dis
1992; 145:1321-1327.
Löfdahl
C-G, Andreasson E, Svensson K and Ericsson A. Budesonide/formoterol
in a single inhaler improves health status in patients with COPD
without increasing healthcare costs. Eur Resp
J 2003; 22, Suppl 45; 50s.
Miravitlles
M, Mayordomo C, Artés M, Sánchez-Agudo L, Nicolau F,
Segú JL. Treatment of chronic obstructive pulmonary
disease and its exacerbations in general practice. Respir
Med 1999; 93:173-9.
Osman
LM, Godden DJ, Friend JAR, Legge JS, Douglas JG. Quality of
life and hospital re-admission in patients with chronic obstructive
pulmonary disease. Thorax 1997; 52: 67-71.
Szafranski
W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson
S, Olsson H. Efficacy and safety of budesonide/formoterol in
the management of chronic obstructive pulmonary disease. Eur
Resp J 2003; 21: 74-81.
Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship
between exacerbation frequency and lung function decline in chronic
obstructive pulmonary disease. Thorax 2002; 57:847-52).
Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1418-22.
|
